Scottish Advisory Organization Recommends Elmiron for Bladder Pain Syndrome

November 25, 2019

The Scottish Medicines Consortium has recommended that Scotland’s healthcare system provide coverage for Consilient Health’s Elmiron (pentosan polysulfate) for treating bladder pain syndrome (BPS).

The drug is currently indicated for treating BPS that is characterized by either bladder hemorrhages or Hunner’s lesions in adults with moderate to severe pain and urgent and frequent urination.

The SMC’s recommendation follows Consilient’s agreement to a patient access scheme for coverage by NHS Scotland.

View today's stories